Lupin gets USFDA nod to market generic anti-bacterial drug
Lupin has received final approval from the USFDA to market generic anti-bacterial drug metronidazole tablets in strengths of 250 mg and 500 mg
New Delhi: Drug maker Lupin Ltd on Wednesday said it has received US health regulator’s nod to market generic version of Flagyl tablets, a drug used to treat bacterial infections, in the American market.
The company has received final approval from the US Food and Drug Administration (US FDA) to market metronidazole tablets in strengths of 250 mg and 500 mg, Lupin said in a statement.
The Mumbai-based company’s product is a generic version of G.D. Searle LLC’s Flagyl tablets which are indicated in the treatment of a wide variety of bacterial infections.
As per IMS MAT sales June data, Flagyl tablets had sales of $44.1 million in the US market. Lupin shares on Wednesday closed 1.39% up at Rs995 per scrip on BSE.
- GSTN developing tools for tax authorities to analyse data to check tax evasion
- Biocon receives EIR from USFDA for its Bengaluru facility producing sterile
- Infosys to now focus on relentless execution, stability concerns addressed: Nandan Nilekani
- McDonald’s adopts eco-friendly cutlery in West and South India
- US investors seek Chanda Kochhar’s ouster from ICICI Bank